Compounds > buthalital
Page last updated: 2024-12-10

buthalital

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

buthalital: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3032321
CHEMBL ID2110937
CHEBI ID134980
SCHEMBL ID10712350
MeSH IDM0045516

Synonyms (28)

Synonym
buthalital
CHEBI:134980
5-(2-methylpropyl)-5-prop-2-enyl-2-sulfanylidene-1,3-diazinane-4,6-dione
5-allyl-5-isobutyl-2-thiobarbituric acid
4,6(1h,5h)-pyrimidinedione, dihydro-5-(2-methylpropyl)-5-(2-propenyl)-3-thioxo-
k5vbq75636 ,
468-65-5
baylinal
buthalial
unii-k5vbq75636
thialbutone
barbituric acid, 5-allyl-5-isobutyl-2-thio-
buthalitone
buthalital [mi]
4,6(1h,5h)-pyrimidinedione, dihydro-5-(2-methylpropyl)-5-(2-propen-1-yl)-2-thioxo-
dihydro-5-(2-methylpropyl)-5-(2-propen-1-yl)-2-thioxo-4,6(1h,5h)-pyrimidinedione
5-allyl-5-(2-methylpropyl)-2-thiobarbituric acid
SCHEMBL10712350
CHEMBL2110937
DTXSID50196942
CS-6707
HY-U00057
dihydro-5-(2-methylpropyl)-5-isopropyl-2-thioxopyrimidine-4,6(1h,5h)-dione
Q27281988
DTXSID50862079
6-hydroxy-5-(2-methylpropyl)-5-(prop-2-en-1-yl)-2-sulfanylidene-2,5-dihydropyrimidin-4(3h)-one
buthalital (bayinal, baytinal, thialbutal, transithal, ulbreval)
5-(2-methylpropyl)-5-(prop-2-en-1-yl)-2-sulfanylidene-1,3-diazinane-4,6-dione
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
barbituratesMembers of the class of pyrimidones consisting of pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and its derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-199023 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.23 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
barbituric acid
barbituric acid: RN given refers to parent cpd; structure from Merck Index, 9th ed, #966. barbituric acid : A barbiturate, the structure of which is that of perhydropyrimidine substituted at C-2, -4 and -6 by oxo groups. Barbituric acid is the parent compound of barbiturate drugs, although it is not itself pharmacologically active.		2.3320barbituratesallergen;
xenobiotic
tabun
tabun: proposed as military nerve gas and exptl cholinesterase inhibitor; extremely poisonous; structure		1.9410
methylergonovine
Methylergonovine: A homolog of ERGONOVINE containing one more CH2 group. (Merck Index, 11th ed)		1.9410ergoline alkaloid
thiobarbituric acid
thiobarbituric acid: RN given refers to parent cpd. 2-thiobarbituric acid : A barbiturate, the structure of which is that of barbituric acid in which the oxygen at C-2 is replaced by sulfur.		1.9310barbituratesallergen;
reagent
ConditionIndicatedRelationship StrengthStudiesTrials
Anesthesia
A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.		04.37220
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.6330
Female Genital Diseases
[description not available]		01.9310
Genital Diseases, Female
Pathological processes involving the female reproductive tract (GENITALIA, FEMALE).		01.9310
Narcosis
A state of depressed CENTRAL NERVOUS SYSTEM marked by stupor or insensibility.		01.9310
Abortion, Tubal
[description not available]		01.9410
Complication, Postoperative
[description not available]		01.9410
Hemorrhage, Uterine
[description not available]		01.9410
Abortion, Spontaneous
Expulsion of the product of FERTILIZATION before completing the term of GESTATION and without deliberate interference.		01.9410
Postoperative Complications
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.		01.9410
Uterine Hemorrhage
Bleeding from blood vessels in the UTERUS, sometimes manifested as vaginal bleeding.		01.9410
Poisoning
Used with drugs, chemicals, and industrial materials for human or animal poisoning, acute or chronic, whether the poisoning is accidental, occupational, suicidal, by medication error, or by environmental exposure.		01.9410
Polyarthritis
[description not available]		01.9310
Rheumatoid Arthritis
[description not available]		01.9310
Arthritis
Acute or chronic inflammation of JOINTS.		01.9310
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		01.9310
Contracture
Prolonged shortening of the muscle or other soft tissue around a joint, preventing movement of the joint.		01.9310
Periarthritis
Inflammation of the tissues around a joint. (Dorland, 27th ed)		01.9310